Major Scope

  •  Colon and Rectal Surgery
  •  General Surgery
  •  Gynecologic Oncology
  •  Plastic Surgery
  •  Neurological Surgery
  •  Orthopaedic Surgery
  •  Orthopaedic Surgery of the Spine
  •  Neonatal Surgery
  •  Prenatal Surgery
  •  Trauma Surgery
  •  Surgical Intensivists, Specializing In Critical Care Patients
  •  Thoracic Surgery
  •  Congenital Cardiac Surgery
  •  Thoracic Surgery-Integrated
  •  Vascular Surgery

Abstract

Citation: Clin Surg. 2020;5(1):2899.Research Article | Open Access

Efficacy and Safety of Pilocarpine Hydrochloride in the Treatment of Voiding Difficulty in Patients with Detrusor Underactivity

Kanya Kaga1, Tomohiko Kamasako1, Mayuko Kaga1, Miki Fuse1, Mitsuru Ishizuka2 and Tomonori Yamanishi1*

1Department of Urology, Continence Center, Dokkyo Medical University, Tochigi, Japan
2Department of Surgery, Continence Center, Dokkyo Medical University, Tochigi, Japan

*Correspondance to: Tomonori Yamanishi 

 PDF  Full Text DOI: 10.25107/2474-1647.2899

Abstract

Background and Objective: We previously examined the contractile effect of pilocarpine on pig and human isolated bladder smooth muscle. The present study exploratorily investigated the efficacy and safety of pilocarpine for the treatment of voiding difficulty due to detrusor underactivity. Methods: Patients with voiding symptoms, maximum urinary flow rate (Qmax) ≤ 10 mL/s, and Post-Void Residual urine volume (PVR) ≥ 50 mL, and diagnosed with detrusor underactivity in a pressure-flow study, were treated with pilocarpine (a dose of 5 mg 3 times daily) for 8 weeks. The primary endpoint was the change in Qmax vs. baseline. The secondary endpoints were changes in the International Prostate Symptom Score (IPSS; total IPSS, voiding symptoms including sensation of incomplete emptying), Quality of Life (QOL) score, and average urinary flow rate (Qave). Results: In uroflowmetry, significant changes were demonstrated (Qmax, 9.1 ± 4.6 to 12.9 ± 5.5 ml/s, P=0.0313; Qave, 6.1 ± 5.3 to 8.8 ± 6.3 ml/s, P=0.0039; voided volume, 158.8 ± 114.5 to 186.8 ± 110.0 ml, P=0.0273; and PVR, 222.7 ± 122.3 to 102.4 ± 92.9 ml, P=0.0020). IPSS total score and IPSS voiding symptom score were significantly decreased after the treatment (IPSS total score, 15.8 ± 9.4 to 12.1 ± 9.0 points, P=0.0039; voiding symptom subtotal score, 9.3 ± 6.1 to 7.3 ± 5.7 points, P=0.0469). Conclusion: Pilocarpine improved voiding symptoms scores and urinary flow rates, decreasing PVR. Pilocarpine appeared to be safe and effective for the treatment of detrusor underactivity in patients with voiding difficulty due to detrusor underactivity.

Keywords

Cite the article

Kaga K, Kamasako T, Kaga M, Fuse M, Ishizuka M, Yamanishi T. Efficacy and Safety of Pilocarpine Hydrochloride in the Treatment of Voiding Difficulty in Patients with Detrusor Underactivity. Clin Surg. 2020; 5: 2899..

Journal Basic Info

  • Impact Factor: 2.395**
  • H-Index: 8
  • ISSN: 2474-1647
  • DOI: 10.25107/2474-1647
  • NLM ID: 101702548

Search Our Journal

Journal Indexed In

Articles in PubMed

Sildenafil Transiently Delays Early Alveolar Bone Healing of Tooth Extraction Sockets
 PubMed  PMC  PDF  Full Text
Mesh Sprayer Device with Liquefied Mesh Delivery System: Proposed Alternative for Currently Available Meshes in Hernia Repair and Supplement to Abdominal Closure
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Laparoscopic Hepatectomy Reduces the Incidence of Postoperative Hypoalbuminemia: A Propensity Score Matching Analysis with Open Hepatectomy
 Abstract  PDF  Full Text
The Impact of ?-Blocker on Coronary Flow Reserve in a Case with Coronary Artery Ectasia
 PDF  Full Text
View More...